Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Orion Corporation, Orion Pharma
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females aged 18-60 years with documented diagnosis of asthma
Prebronchodilator forced expiratory volume in one second (FEV1) at least 80% of the predicted value
The asthma should be stable on the same regular treatment for at least 4 weeks before screening.
You may not be if
Use of oral, parenteral or rectal corticosteroids within 4 weeks preceding the screening
Respiratory infection within 4 weeks preceding the screening
Any condition requiring regular concomitant treatment or likely to need concomitant treatment during the study with medicinal products which have pharmacokinetic interactions with budesonide
Any disorder or clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study
Clareo Health | Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics
